Mr. McCoy, Civica’s COO, will succeed Martin VanTrieste at the helm, effective June 1, according to a news release. Mr. VanTrieste, who came out of retirement four years ago to lead Civica, will continue serving on the company’s board.
The leadership transition comes as Civica is building a drug manufacturing facility in Petersburg, Va., which is expected to be operational in early 2024. In March, the company also announced plans to manufacture and distribute three insulins at a discounted price.
Before joining Civica, Mr. McCoy worked at Abbott for more than three decades, according to the release.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
